XML 92 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-based payments (Tables)
12 Months Ended
Dec. 31, 2023
Share-based payments  
Schedule for expense recognized for the equity-settled programs

The expense recognized for share-based payments during the years ended December 31 is as follows:

    

2021

    

2022

    

2023

EUR k

EUR k

EUR k

Prior VSOP

 

(624)

 

(131)

 

(10)

New VSOP

 

(572)

 

95

 

(19)

LTIP Stock Options

 

(12,472)

 

(5,562)

 

(2,944)

LTIP RSUs

 

(705)

 

(3,108)

 

(4,072)

RSU Supervisory board

 

(566)

 

(478)

 

(652)

Total

 

(14,939)

 

(9,184)

 

(7,697)

Prior VSOP  
Share-based payments  
Schedule of reconciliation of outstanding awards

    

2021

    

2022

    

2023

Outstanding at the beginning of the period

7,951,265

6,426,365

5,614,246

Granted during the period

 

Forfeited during the period

 

(34,859)

(11,091)

Exercised during the period

(1,524,900)

(777,260)

Outstanding at the end of the period

 

6,426,365

5,614,246

5,603,155

Thereof vested

 

6,365,422

5,509,886

5,588,513

Thereof exercisable

 

none

none

none

Schedule of share-based payments expenses

The expense recognized for this share-based payment plan during the years ended December 31 is as follows:

2021

2022

2023

    

EUR k

    

EUR k

    

EUR k

Cost of Sales

(9)

Selling and distribution expenses

(25)

(8)

(6)

Research and development expenses

 

(369)

 

(45)

 

46

General and administrative expenses

 

(230)

 

(78)

 

(41)

Total

 

(624)

 

(131)

 

(10)

New VSOP  
Share-based payments  
Schedule of reconciliation of outstanding awards

The number of awards in the New VSOP program granted to key employees developed as follows:

    

2021

    

2022

    

2023

Outstanding at the beginning of the period

906,595

 

349,424

 

102,108

Granted during the period

 

 

Forfeited during the period

(99,696)

Exercised during the period

(557,171)

(147,620)

(69,246)

Outstanding at the end of the period

 

349,424

102,108

32,862

Thereof vested

88,464

59,942

32,862

Thereof exercisable

 

88,464

59,942

Schedule of share-based payments expenses

The expense recognized for employee services received during the years ended December 31, 2023, 2022, and 2021 is shown in the following table:

    

2021

    

2022

    

2023

EUR k

EUR k

 

EUR k

Research and development expenses

 

(349)

69

(31)

Selling and distribution expenses

 

(188)

23

General and administrative expenses

 

(35)

3

12

Total

 

(572)

95

(19)

Former Chief Executive Officer Grant  
Share-based payments  
Schedule of inputs used in the measurement of the fair value at grant date

Weighted average fair value per option

    

EUR 57.40

Weighted average share price (10-days VWAP before grant date)

 

EUR 50.01

Exercise price (USD 11.90)

 

EUR 10.04

Expected volatility (%)

 

62.06

%

Expected life (years)

 

1.82

Risk-free interest rate (%)

 

0.07 - 1.48

%

First tranche:

Weighted average fair value per option

    

EUR 48.27

Weighted average share price (actual 10-days VWAP before grant date, USD 81.03)

 

EUR 67.12

Exercise price (USD 52.96)

 

EUR 43.87

Expected volatility (%)

 

62.27

%

Expected life (years)

 

1.78

Risk-free interest rate (%)

 

0.07 - 1.50

%

Second tranche:

Weighted average fair value per option

    

EUR 24.36

Weighted average share price (estimated by Monte Carlo simulation to be USD 98.36)

 

EUR 81.48

Exercise price (estimated by Monte Carlo simulation to be USD 98.36)

 

EUR 81.48

Expected volatility (%)

 

62.27

%

Expected life (years)

 

2.23

Risk-free interest rate (%)

 

0.07 - 1.50

%

Third tranche:

Weighted average fair value per option

    

EUR 20.01

Weighted average share price (estimated by Monte Carlo simulation to be USD 98.57)

 

EUR 81.65

Exercise price (estimated by Monte Carlo simulation to be USD 98.57)

 

EUR 81.65

Expected volatility (%)

 

62.27

%

Expected life (years)

 

2.66

Risk-free interest rate (%)

 

0.07 - 1.50

%

Weighted average fair value per option

    

EUR 0.65

Weighted average share price (30-days VWAP after grant date)

 

EUR 77.73

Exercise price (USD 88.16)

 

EUR 77.73

Expected volatility (%)

 

73.00

%

Expected life (years)

 

2.15

Risk-free interest rate (%)

 

0.08 - 0.49

%

Weighted average fair value per option

    

EUR 17.56

Weighted average share price (20-day VWAP before grant date)

 

EUR 56.51

Exercise price (USD 84.03)

 

EUR 70.92

Expected volatility (%)

70.95

%

Expected life (years)

 

4.5

Risk-free interest rate (%)

0.099  –  0.903

%

Weighted average fair value per option

    

EUR 17.56

Weighted average share price (20-days VWAP before grant date)

 

EUR 41.81

Exercise price (USD 84.03)

 

EUR 46.16

Expected volatility (%)

75.13

%

Expected life (years)

 

4.6

Risk-free interest rate (%)

0.075  –  0.704

%

Weighted average fair value per option

    

EUR 14.31

Weighted average share price (30-days VWAP after grant date)

 

EUR 30.67

Exercise price (USD 34.87)

 

EUR 30.67

Expected volatility (%)

 

72.17

%

Expected life (years)

 

2.16

Risk-free interest rate (%)

 

0.40 - 1.15

%

Weighted average fair value per option

    

EUR 4.86

Weighted average share price (10 - day VWAP before grant date)

 

EUR 15.07

Exercise price (USD 19.35)

 

EUR 18.37

Expected volatility (%)

 

73.87 - 86.09

%

Expected life (years)

 

2.33

Risk-free interest rate (%)

 

2.34 - 3.21

%

Weighted average fair value per option

    

EUR 6.81

 

Weighted average share price (10-days VWAP before grant date)

EUR 17.45

 

Exercise price (USD 19.28)

 

EUR 17.45

Expected volatility (%)

 

50.91

%

Expected life (years)

 

2.16

Risk-free interest rate (%)

 

2.67

%

Weighted average fair value per option

    

EUR 3.55

Weighted average share price (10-day VWAP before grant date)

 

EUR 6.12

Exercise price (USD 6.66)

 

EUR 6.12

Expected volatility (%)

 

75.0

%

Expected life (years)

 

3.39

Risk-free interest rate (%)

 

3.70

%

Restricted Stock Units  
Share-based payments  
Schedule of share-based payments expenses

    

2021

    

2022

    

2023

EUR k

EUR k

EUR k

Cost of Sales

(331)

Research and development expenses

 

(240)

 

(909)

 

(1,719)

Selling and distribution expenses

 

(82)

 

(199)

 

(269)

General and administrative expenses

 

(383)

 

(2,000)

 

(1,753)

Total

 

(705)

 

(3,108)

 

(4,072)